文献速递真菌感染

艾沙康唑治疗侵袭性霉菌病的药效学:半乳甘露聚糖用于实时监测治疗反应的作用

Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.
PubMed 文献 · Clin Infect Dis · 2017-01-01

本研究基于三期临床试验数据,分析基线半乳甘露聚糖指数(GMI)阳性患者早期GMI变化与死亡率及总体应答的关系,并进行艾沙康唑的药代/药效分析。结果显示第7天GMI较基线升高>0.25单位显著增加死亡风险(HR 9.766),每降低1单位成功治疗几率翻倍(OR 2.154)。AUC:EC50为108.6预计可使治疗结束时GMI转阴。

要点

  • 第7天GMI较基线升高>0.25单位与死亡风险显著增加相关(HR 9.766)。
  • 第7天GMI每降低1单位,成功治疗几率翻倍(OR 2.154)。
  • 艾沙康唑AUC:EC50为108.6预计可使治疗结束时GMI转阴。

核心结论

  • 早期GMI变化趋势对患者结局有高度预测价值。
  • 第7天GMI升高>0.25单位可结合临床体征考虑触发治疗调整(需验证后)。
  • 数据提示可改善生存约10倍、阳性结局约3倍。

研究设计与样本

  • 基于三期临床试验的回顾性分析,纳入基线GMI≥0.5且治疗期间有连续GMI的患者。
  • 总体纳入158例患者,其中78例艾沙康唑患者纳入PK/PD建模。
  • 使用Cox比例风险模型和逻辑回归分析早期GMI变化与死亡率及总体应答的相关性。

主要发现

  • 第7天GMI较基线升高>0.25单位者中,存活者3/130、死亡者9/28,死亡风险显著增加(HR 9.766;95%CI 4.356-21.9;P<.0001)。
  • 第7天GMI每降低1单位,成功治疗几率翻倍(OR 2.154;95%CI 1.173-3.955)。
  • 艾沙康唑AUC:EC50为108.6预计可使治疗结束时GMI转阴。

关键数值与推荐

  • 基线GMI阳性定义为≥0.5。
  • 第7天GMI较基线升高>0.25单位定义为显著升高。
  • AUC:EC50为108.6预计与治疗结束时GMI转阴相关。

临床怎么用

  • 治疗侵袭性曲霉病时,可早期监测GMI变化作为治疗反应的替代指标。
  • 第7天GMI升高>0.25单位提示死亡风险增加,可结合临床体征考虑调整治疗(需验证)。
  • 艾沙康唑AUC:EC50达到108.6可能有助于实现GMI转阴。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND.: The ability to make early therapeutic decisions when treating invasive aspergillosis using changes in biomarkers as a surrogate for therapeutic response could significantly improve patient outcome. METHODS.: Cox proportional hazards model and logistic regression were used to correlate early changes in galactomannan index (GMI) to mortality and overall response, respectively, from patients with positive baseline GMI (≥0.5) and serial GMI during treatment from a phase 3 clinical trial for the treatment of invasive mold disease. Pharmacokinetic/pharmacodynamic (PK/PD) analysis in patients with isavuconazole plasma concentrations was conducted to establish the exposure necessary for GMI negativity at the end of therapy. RESULTS.: The study included 158 patients overall and 78 isavuconazole patients in the PK/PD modeling. By day 7, GMI increases of >0.25 units from baseline (3/130 survivors; 9/28 who died) significantly increased the risk of death compared to those with no increase or increases <0.25 (hazard ratio, 9.766; 95% confidence interval [CI], 4.356-21.9; P < .0001). For each unit decrease by day 7 from baseline, the odds of successful therapy doubled (odds ratio, 2.154; 95% CI, 1.173-3.955). An area under the concentration-versus-time curve over half-maximal effective concentration (AUC:EC50) of 108.6 is estimated to result in a negative GMI at the end of isavuconazole therapy. CONCLUSIONS.: Early trends in GMI are highly predictive of patient outcome. GMI increases by day 7 could be considered in context of clinical signs to trigger changes in treatment, once validated. Our data suggest that this improves survival by 10-fold and positive outcome by 3-fold. These data have important implications for individualized therapy for patients and clinical trials. CLINICAL TRIALS REGISTRATION.: NCT00412893.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kovanda LL, Kolamunnage-Dona R, Neely M, et al. Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. Clin Infect Dis. 2017. PMID: 28472247. doi:10.1093/cid/cix198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。